HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: iovs.09-3569v1 50/11/5328    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Giansanti, F. Articles by Menchini, U. PubMed PubMed Citation Articles by Giansanti, F. Articles by Menchini, U.

Intravitreal Infliximab Clearance in a Rabbit Model: Different Sampling Methods and Assay Techniques

From the Departments of ¹Oto-Neuro-Ophthalmological Surgical Sciences, Eye Clinic, and ³Biochemical Sciences, University of Florence, Florence, Italy.

Corresponding author: Fabrizio Giansanti, V. le Morgagni 85, Florence 50143, Italy; fabriziogiansanti{at}interfree.it.

Purpose. To investigate the clearance of intravitreal infliximab with the use of different sampling techniques and immunoassay methods in rabbits.

Methods. Infliximab (1.6 mg) was intravitreally injected into both eyes of 47 rabbits. Two approaches were used to collect the vitreous: the classic method and a microsampling technique. Whereas the classic method consists of collection of the whole vitreous after enucleation, the microsampling technique consisted of the aspiration of small (10–15 µL) samples with a 200-µL syringe. Samples were taken from 30 minutes to 40 days using both methods and were then compared. Infliximab concentration was estimated with competitive ELISA, dot blot analysis, and Western blot analysis.

Results. The vitreous half-life of infliximab was estimated to be 6.5 ± 0.6 days. The data indicated monoexponential decay reaching its conclusion after approximately 40 days. This decay was preceded by 4-day-long diffusion in the vitreous. Microsampling proved to be effective in the vitreous collection, giving statistically comparable signals (± 4%, P = 0.68) with respect to the classic procedure. ELISA proved to be the best analytical technique—especially if coupled with microsamplings—because of its lower detection limit, precision, and reduced amount of sample needed. No differences were observed between half-life values obtained by ELISA and dot blot analysis (P = 0.081) and Western blot analysis (P = 0.614).

Conclusions. The findings of this study added to the knowledge of infliximab clearance in the vitreous and confirmed the validity of a microsampling technique that was compared with the classic one. ELISA was found to be the best analytical technique when using microsampling.